TripSitter Clinic Ltd. (TSTTF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.08: the stock has moved about 92% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTripSitter Clinic Ltd. (TSTTF) trades at $0.0219. TripSitter Clinic Ltd. operates a virtual clinic and tele-health platform, connecting patients with licensed physicians for low-dose oral ketamine treatment programs. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for TSTTF: TSTTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
TripSitter Clinic Ltd. (TSTTF) Healthcare & Pipeline Overview
TripSitter Clinic Ltd. provides a virtual clinic and tele-health platform, connecting patients with physicians for prescribed low-dose oral ketamine treatment programs. Focusing on mental health, the company offers a subscription-based model covering consultation, medication, and therapy sessions, serving clients across multiple states in the United States.
What Is the Investment Thesis for TSTTF?
TripSitter Clinic Ltd. presents a unique investment opportunity within the telehealth and mental health sectors. The company's focus on low-dose oral ketamine treatment for mental health conditions positions it within a growing market for alternative therapies. Key value drivers include the expansion of its service offerings to new states, increased patient adoption of telehealth services, and positive clinical outcomes from its treatment programs. With a negative P/E ratio of -100.42, the company's profitability is a key area to monitor. Growth catalysts include ongoing research supporting the efficacy of ketamine treatment, favorable regulatory changes expanding access to telehealth services, and strategic partnerships with healthcare providers and insurance companies. Potential risks include regulatory hurdles related to ketamine prescription, competition from established telehealth providers, and the need for continuous innovation to maintain a competitive edge. The company's low Beta of 0.08 suggests low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
TSTTF Key Highlights
Operates a virtual clinic and tele-health platform focused on low-dose oral ketamine treatment.
- Offers a comprehensive treatment subscription plan including consultation, medication, and therapy sessions.
- Serves clients in multiple states across the United States, including California, Florida, and New York.
- Addresses mental health conditions such as depression, anxiety, PTSD, bipolar disorders, and OCD.
- P/E ratio of -100.42 indicates the company is currently not profitable.
Who Are TSTTF's Competitors?
TSTTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| VEEV Veeva Systems Inc. | $273.33 | -3.05% | $44.4B | 90 5-pillar |
| GEHC GE HealthCare Technologies Inc. | $64.29 | +0.48% | $29.0B | 61 5-pillar |
| TEM Tempus AI, Inc. | $76.63 | +0.17% | $13.4B | 32 5-pillar |
| TXG 10x Genomics, Inc. | $93.50 | +5.34% | $11.9B | 39 5-pillar |
| BTSG BrightSpring Health Services, Inc. | $60.25 | +5.22% | $11.8B | 83 5-pillar |
| HNGE Hinge Health, Inc. | $97.67 | -0.28% | $7.56B | 93 5-pillar |
| HQY HealthEquity, Inc. | $90.04 | +0.75% | $7.53B | 91 5-pillar |
| DOCS Doximity, Inc. | $27.93 | -2.00% | $5.22B | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TSTTF's Key Strengths?
Virtual platform provides convenient access to treatment.
- Focus on low-dose oral ketamine treatment for mental health.
- Comprehensive subscription plan includes multiple services.
- Experienced team of physicians and medical practitioners.
What Are TSTTF's Weaknesses?
Limited geographic reach (currently serves select states).
- Reliance on regulatory approval for ketamine prescription.
- Negative P/E ratio indicates current lack of profitability.
- Competition from established telehealth providers.
What Could Drive TSTTF Stock Higher?
Expansion into new states, increasing the company's market reach.
- Positive clinical outcomes from ketamine treatment programs, enhancing the company's reputation.
- Strategic partnerships with healthcare providers, expanding access to patients.
- Increased adoption of telehealth services, driving revenue growth.
What Are the Key Risks for TSTTF?
Regulatory changes impacting ketamine prescription and telehealth services.
- Competition from established telehealth providers and pharmaceutical companies.
- Negative publicity or safety concerns related to ketamine treatment.
- Limited liquidity due to OTC Other classification.
- Dependence on a specific niche within the mental health market.
What Are the Growth Opportunities for TSTTF?
- Expansion into New States: TripSitter Clinic Ltd. has the opportunity to expand its services to additional states in the United States. The telehealth market is projected to reach $55.6 billion by 2027, offering a significant opportunity for growth. Entering new markets will require navigating state-specific regulations and building partnerships with local healthcare providers. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Collaborating with established healthcare providers and clinics can expand TripSitter Clinic's reach and credibility. Partnerships can provide access to a broader patient base and facilitate integration with existing healthcare systems. The market for healthcare partnerships is growing, with increasing emphasis on integrated care models. Timeline: Ongoing.
- Development of New Treatment Programs: Expanding the range of mental health conditions treated on the platform can attract a wider patient base. Research into new applications of low-dose ketamine and other innovative therapies can differentiate TripSitter Clinic from competitors. The market for mental health treatments is constantly evolving, with ongoing research into new therapies. Timeline: Ongoing.
- Increased Marketing and Awareness Campaigns: Investing in marketing and awareness campaigns can increase patient adoption of TripSitter Clinic's services. Targeted advertising and educational content can reach individuals who may benefit from ketamine treatment. The market for digital marketing in healthcare is growing, with increasing emphasis on personalized and data-driven campaigns. Timeline: Ongoing.
- Integration with Insurance Providers: Securing coverage from major insurance providers can improve affordability and accessibility of TripSitter Clinic's services. Negotiating reimbursement rates and demonstrating the cost-effectiveness of ketamine treatment can facilitate insurance coverage. The market for telehealth reimbursement is evolving, with increasing recognition of the value of virtual care. Timeline: Ongoing.
What Are TSTTF's Competitive Advantages?
- Proprietary tele-health platform for delivering ketamine treatment.
- Network of licensed physicians and medical practitioners.
- Focus on a specific niche within the mental health market.
- Subscription-based revenue model provides recurring income.
What Does TSTTF Do?
TripSitter Clinic Ltd., headquartered in Toronto, Canada, operates a virtual clinic and tele-health platform that connects patients with licensed physicians who can evaluate and prescribe low-dose oral ketamine treatment programs. The company's platform is designed to address a range of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorders, and obsessive-compulsive disorders (OCD). Founded with the mission to provide accessible and convenient mental health care, TripSitter Clinic leverages technology to bridge the gap between patients and qualified medical professionals. The company's core offering is a comprehensive treatment subscription plan that includes several key components: initial consultation with a licensed physician to determine eligibility for ketamine treatment, prescription of low-dose oral ketamine medication, treatment sessions with a licensed medical practitioner to monitor progress and adjust treatment plans, and ongoing messaging support with a licensed medical practitioner for any questions or concerns. TripSitter Clinic currently serves clients in several states across the United States, including California, Illinois, Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia. By offering a virtual platform, TripSitter Clinic aims to reduce the barriers to mental health treatment, such as geographic limitations and stigma associated with in-person visits. The company's focus on low-dose oral ketamine treatment reflects a growing interest in alternative therapies for mental health conditions that have not responded well to traditional treatments.
What Products and Services Does TSTTF Offer?
- Operates a virtual clinic and tele-health platform.
- Connects patients with licensed physicians for mental health evaluations.
- Prescribes low-dose oral ketamine medication for treatment programs.
- Provides treatment sessions with licensed medical practitioners.
- Offers messaging support with licensed medical practitioners.
- Treats conditions like depression, anxiety, PTSD, bipolar disorders, and OCD.
How Does TSTTF Make Money?
- Generates revenue through subscription-based treatment plans.
- Offers comprehensive packages including consultation, medication, and therapy.
- Partners with physicians and medical practitioners to deliver services.
What Industry Does TSTTF Operate In?
The healthcare information services industry is experiencing rapid growth, driven by increasing adoption of telehealth and virtual care solutions. The market for mental health services is particularly strong, with rising awareness of mental health issues and a growing demand for accessible and convenient treatment options. TripSitter Clinic Ltd. operates within this context, competing with other telehealth providers such as CAFS, ESSI, EVAHF, MDNWF, and NEWUF, while differentiating itself through its focus on low-dose oral ketamine treatment. The industry is subject to evolving regulations and reimbursement policies, which can impact the company's growth and profitability.
Who Are TSTTF's Key Customers?
- Individuals seeking treatment for depression, anxiety, PTSD, bipolar disorders, and OCD.
- Patients who prefer the convenience and accessibility of virtual care.
- Individuals in states where TripSitter Clinic is licensed to operate.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for TripSitter Clinic Ltd. stands at 8.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
TripSitter Clinic Ltd. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO John Huber. TSTTF has traded publicly since 2022.
Financial Health
TripSitter Clinic Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
TSTTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Virtual platform provides convenient access to treatment.
- Focus on low-dose oral ketamine treatment for mental health.
- Comprehensive subscription plan includes multiple services.
- Experienced team of physicians and medical practitioners.
Bear Case
- Limited geographic reach (currently serves select states).
- Reliance on regulatory approval for ketamine prescription.
- Negative P/E ratio indicates current lack of profitability.
- Competition from established telehealth providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TSTTF Latest News
No recent news available for TSTTF.
TSTTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TSTTF.
Price Targets
Wall Street price target analysis for TSTTF.
TSTTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TSTTF; grades run from A+ (80-100) to F (below 30).
Leadership: John Huber
CEO
John Huber is the CEO of TripSitter Clinic Ltd. His background includes experience in healthcare management and technology. Prior to joining TripSitter Clinic, Huber held leadership positions at various healthcare startups, focusing on digital health solutions and patient engagement. He has a proven track record of building and scaling innovative healthcare businesses. Huber's expertise lies in leveraging technology to improve access to care and enhance patient outcomes. He holds a degree in Business Administration from a leading university.
Track Record: Under John Huber's leadership, TripSitter Clinic Ltd. has expanded its services to multiple states and established a strong presence in the telehealth market. He has overseen the development of the company's virtual platform and the implementation of its comprehensive treatment subscription plan. Huber has also focused on building strategic partnerships and securing regulatory approvals for ketamine prescription. Key milestones under his tenure include the launch of new treatment programs and the expansion of the company's network of physicians and medical practitioners.
TSTTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that TripSitter Clinic Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information, price volatility, and lack of liquidity. The OTC Other tier is distinct from listed exchanges which have more stringent listing requirements and continuous reporting obligations.
- OTC Tier: OTC Other
- Limited Disclosure: OTC Other companies may have minimal reporting requirements, making it difficult to assess their financial health and operations.
- Low Liquidity: Limited trading volume can make it challenging to buy or sell shares without impacting the price.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volume and potential for manipulation.
- Regulatory Scrutiny: OTC companies may face less regulatory oversight compared to those listed on major exchanges.
- Going Concern Risk: Companies on the OTC Other tier may be at higher risk of financial distress or bankruptcy.
- Verify the company's management team and their track record.
- Review available financial statements and assess the company's financial health.
- Research the company's business model and competitive landscape.
- Understand the regulatory environment and potential risks.
- Assess the liquidity of the stock and potential trading challenges.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and claims.
- Operation of a virtual clinic and tele-health platform.
- Connection of patients with licensed physicians.
- Prescription of low-dose oral ketamine medication for treatment programs.
- Treatment of mental health conditions such as depression, anxiety, and PTSD.
TripSitter Clinic Ltd. Healthcare Stock: Key Questions Answered
Is TSTTF a good stock to buy?
Stock Expert AI does not rate TSTTF buy, sell or hold. TripSitter Clinic Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TSTTF stock price today?
The last price recorded on this page for TripSitter Clinic Ltd. (TSTTF) is $0.0219, as of the Oct 2, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about TSTTF stock?
As of 2026-03-16, there is no readily available analyst coverage for TSTTF stock due to its OTC Other listing and limited market capitalization. The company's P/E ratio of -100.42 suggests it is not currently profitable.
What are the key factors to evaluate for TSTTF?
Evaluate TSTTF on fundamentals, analyst consensus, and risk factors. TripSitter Clinic Ltd. presents a unique investment opportunity within the telehealth and mental health sectors. Not financial advice.
How frequently does TSTTF data refresh on this page?
TSTTF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TSTTF's recent stock price performance?
TripSitter Clinic Ltd. (TSTTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Virtual platform provides convenient access to treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TSTTF overvalued or undervalued right now?
TripSitter Clinic Ltd. (TSTTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TSTTF before investing?
Before investing in TripSitter Clinic Ltd. (TSTTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stock investments carry higher risks due to limited liquidity and disclosure.